NCT07148947View on ClinicalTrials.gov

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm
Interventions
DRUG

Pacritinib

Given PO

DRUG

Decitabine

Given IV

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Azacitidine

Given IV or SC

OTHER

Survey Administration

Ancillary studies

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Swedish Orphan Biovitrum
All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

University of Washington

OTHER